Breakdown | |||
TTM | Jun 2024 | Jun 2023 | Jun 2022 |
---|---|---|---|
Income Statement | Total Revenue | ||
16.93M | 18.32M | 12.87M | 9.61M | Gross Profit |
2.47M | 3.72M | 969.66K | 531.02K | EBIT |
-2.55M | -526.04K | 248.05K | -116.56K | EBITDA |
-2.76M | -11.13K | 409.43K | -12.54K | Net Income Common Stockholders |
-3.40M | -225.25K | 740.99K | -2.89K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
1.12M | 123.55K | 174.02K | 373.53K | Total Assets |
9.84M | 9.19M | 5.63M | 5.35M | Total Debt |
4.67M | 4.63M | 3.36M | 4.06M | Net Debt |
3.55M | 4.51M | 3.19M | 3.68M | Total Liabilities |
8.19M | 8.55M | 4.77M | 5.27M | Stockholders Equity |
1.65M | 639.79K | 861.83K | 78.47K |
Cash Flow | Free Cash Flow | ||
-2.14M | -53.64K | 45.19K | 188.69K | Operating Cash Flow |
-2.24M | -53.64K | 63.48K | 312.98K | Investing Cash Flow |
-1.35M | -78.80K | -18.29K | -124.30K | Financing Cash Flow |
4.39M | 78.75K | -277.26K | 14.89K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $42.21B | 9.43 | 19.35% | 1.05% | 2.12% | 1.63% | |
75 Outperform | $4.62B | 7.58 | 16.52% | 1.56% | 8.10% | 20.03% | |
74 Outperform | $21.74B | 7.34 | 27.40% | 0.76% | 11.74% | 25.66% | |
69 Neutral | $10.62B | 7.52 | 20.38% | 0.84% | 5.86% | 12.20% | |
67 Neutral | $32.92B | 8.75 | 14.30% | 1.60% | 3.47% | 4.22% | |
48 Neutral | $1.99B | 33.30 | -7.66% | 0.21% | 1.34% | -8297.75% | |
39 Underperform | ― | -287.64% | ― | 2.84% | ― |
Lakeside Holding Limited announced leadership changes with the resignation of Mr. Shuai Li as chief operating officer, effective December 9, 2024. His departure was amicable, and he will continue to serve on the board of directors. Mr. Lan Su has been appointed as the new chief operating officer, bringing experience from his role as general manager of a company subsidiary and a background in sales and management in the pharmaceutical industry.